Researchers sought to identify prognostic factors for survival in patients with newly diagnosed multiple myeloma.

Background: Monoclonal free light chains (FLCs) frequently cause rapidly progressive renal failure in patients with multiple myeloma. Immunoassays which provide quantitative measurement of FLCs in ...

Being obese at the time of MGUS diagnosis was associated with a 27% increase in the risk of progression to MM.

analysis of serum free light chain ratio analysis in patients with dialysis-dependent renal failure. When using an abnormal serum FLC ratio as an indication of underlying multiple myeloma ...

Janssen has submitted a new combination regimen for its blockbuster multiple myeloma drug Darzalex ... the rare and potentially fatal disease light chain amyloidosis. The original IV version ...

Johnson & Johnson is in pole position to bring a drug targeting GPRC5D to market as a new therapeutic approach to multiple myeloma ... cells and serum fee light chain biomarkers that indicate ...

Multiple myeloma is a rare haematologic malignancy, representing about 1–2% of all cancers and 17% of haematologic malignancies in the US, predominantly affecting older adults and more common in ...

Dysphagia is an uncommon presentation of systemic immunoglobulin light-chain (AL) amyloidosis with multiple myeloma (MM). Gastrointestinal (GI) involvement usually manifests with altered motility, ...

Pomalyst (pomalidomide) is a prescription drug that’s used to treat multiple myeloma in adults. Pomalyst is also available as a generic drug. Pomalyst comes as an oral capsule. The active ...

Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are white blood cells that help you fight infection by making antibodies. Multiple myeloma starts in the plasma ...

Firefighters, police officer who responded to 9/11 in World Trade Center do have an increased risk of multiple myeloma. There are some other well-defined occupational exposures. For instance ...